HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Anesthesiology63 papers

Drug-induced myelopathy

Last edited: 2 h ago

Overview

Drug-induced myelopathy refers to a neurological syndrome characterized by damage to the spinal cord, often resulting from the toxic effects of certain medications. This condition can manifest as a spectrum of motor and sensory deficits, including spasticity, weakness, and sensory disturbances, primarily affecting the lower extremities. It is clinically significant due to its potential for irreversible neurological damage and significant morbidity. Patients at risk include those receiving long-term or high-dose treatment with specific analgesics and muscle relaxants, particularly those with spinal administration. Early recognition and intervention are crucial in day-to-day practice to prevent permanent disability and optimize patient outcomes 16101820.

Pathophysiology

The pathophysiology of drug-induced myelopathy often involves direct neurotoxicity or interference with critical cellular processes within the spinal cord. Certain drugs, such as muscle relaxants and analgesics, can disrupt normal neurotransmission and homeostasis. For instance, α2-adrenoceptor agonists like tizanidine and GABAergic modulators like gabapentin can affect spinal cord function by altering descending inhibitory pathways and modulating excitatory neurotransmitter release, respectively 35112333. Additionally, voltage-gated calcium channel blockers like mibefradil and Na+ channel blockers like lamotrigine can interfere with neuronal excitability and synaptic transmission, leading to myelopathic changes 3540. These disruptions can result in demyelination, axonal damage, and altered reflex arcs, ultimately manifesting as clinical symptoms 4152641.

Epidemiology

The incidence of drug-induced myelopathy is relatively rare but can be observed in specific patient populations, particularly those undergoing prolonged spinal interventions or receiving high-dose medications. Age appears to be a risk factor, with older adults potentially more susceptible due to decreased metabolic clearance and increased vulnerability of spinal cord tissues 11820. Geographic and sex distributions are less clearly defined, but certain occupational or therapeutic contexts (e.g., chronic pain management) may predispose individuals more frequently 610. Trends over time suggest an increasing awareness and reporting, possibly due to enhanced diagnostic capabilities and heightened clinical vigilance 219.

Clinical Presentation

Patients with drug-induced myelopathy typically present with progressive neurological deficits, often starting with sensory disturbances such as tingling or numbness in the lower extremities. Motor symptoms may include weakness, spasticity, and gait disturbances. Red-flag features include rapid progression of symptoms, asymmetric involvement, and the absence of fever or signs of infection, which help differentiate myelopathy from infectious or inflammatory causes 1101820. Early recognition of these atypical presentations is crucial for timely intervention.

Diagnosis

The diagnostic approach to drug-induced myelopathy involves a thorough clinical evaluation, detailed medication history, and confirmatory imaging and electrophysiological studies. Key diagnostic criteria include:

  • Clinical History: Detailed review of medication use, especially spinal administration of analgesics and muscle relaxants.
  • Neurological Examination: Assessment of motor strength, sensory function, and reflexes.
  • Imaging: MRI of the spine to identify characteristic changes such as T2 hyperintensities in the spinal cord.
  • Electrophysiological Tests: Somatosensory evoked potentials (SSEPs) may show abnormalities indicative of spinal cord dysfunction.
  • Differential Diagnosis: Rule out other causes such as compressive myelopathy, multiple sclerosis, and infectious myelitis.

    • Specific Tests and Cutoffs:

  • MRI Findings: Presence of hyperintense lesions on T2-weighted images 16.
  • SSEP Abnormalities: Prolonged latency or reduced amplitude of N13 component 113.
  • Medication History: Identification of high-risk drugs like tizanidine, gabapentin, or lamotrigine 31018.

    • Differential Diagnosis:

  • Compressive Myelopathy: Distinguished by imaging evidence of spinal cord compression.
  • Multiple Sclerosis: Characterized by disseminated lesions and typical clinical relapses.
  • Infectious Myelitis: Presence of fever, elevated inflammatory markers, and specific infectious etiology 11020.

    • Management

    First-Line Treatment

  • Discontinue Harmful Medications: Immediately stop administration of identified neurotoxic drugs.
  • Supportive Care: Physical therapy to maintain muscle strength and prevent contractures.
  • Symptomatic Relief: Use of muscle relaxants (e.g., baclofen) for spasticity management, titrated carefully to avoid further spinal cord irritation 11820.

    • Specific Interventions:

  • Baclofen: Initial dose 5 mg orally, titrated up as needed, monitoring for respiratory depression 18.
  • Physical Therapy: Daily sessions focusing on mobility and strength exercises 1.

    • Second-Line Treatment

  • Adjunctive Pharmacotherapy: Consider gabapentinoids for neuropathic pain if present, but use cautiously due to potential risks.
  • Steroid Therapy: Short-term high-dose corticosteroids may be considered in acute exacerbations to reduce inflammation 118.

    • Specific Interventions:

  • Gabapentin: Start at 300 mg daily, titrate up to 1800 mg/day 118.
  • Corticosteroids: Methylprednisolone 1-2 g IV over 24 hours, tapered over 5-7 days 118.

    • Refractory Cases / Specialist Escalation

  • Neurology Consultation: For complex cases requiring advanced diagnostic evaluation and management.
  • Rehabilitation Programs: Comprehensive inpatient or outpatient rehabilitation focusing on functional recovery.
  • Experimental Therapies: Consider off-label use of neuroprotective agents under strict monitoring 118.

    • Specific Interventions:

  • Consultation: Referral to a neurologist for specialized care 118.
  • Rehabilitation: Structured programs with multidisciplinary teams 1.

    • Complications

    Common complications include progressive neurological deficits, chronic pain, and secondary musculoskeletal issues like joint contractures. Refractory spasticity and autonomic dysfunction may also arise, necessitating escalation of care 11820. Early recognition and intervention can mitigate these risks, but persistent symptoms may require long-term multidisciplinary management.

    Prognosis & Follow-Up

    The prognosis for drug-induced myelopathy varies widely depending on the extent of spinal cord damage and the timeliness of intervention. Prognostic indicators include the rapidity of symptom onset, severity of initial deficits, and the duration of exposure to neurotoxic agents. Regular follow-up intervals should include:

  • Neurological Assessments: Every 3-6 months initially, then annually if stable.
  • MRI Monitoring: Periodic imaging to assess for progression or resolution of lesions.
  • Functional Evaluations: Assessments of mobility and quality of life to guide rehabilitation efforts.

    • Special Populations

    Elderly Patients

    Elderly patients are particularly vulnerable due to age-related changes in drug metabolism and spinal cord resilience. Close monitoring and dose adjustments are essential 118.

    Pediatrics

    Limited data exist, but caution is advised with spinal drug administration in children due to developing nervous systems. Tailored dosing and vigilant surveillance are recommended 118.

    Comorbidities

    Patients with pre-existing neurological conditions or compromised spinal health (e.g., previous spinal injuries) face heightened risks. Careful medication selection and close monitoring are critical 118.

    Key Recommendations

  • Discontinue High-Risk Medications: Immediately stop administration of drugs known to cause myelopathy (e.g., tizanidine, gabapentin, lamotrigine) 118 (Evidence: Strong).
  • Comprehensive Neurological Evaluation: Conduct thorough clinical and electrophysiological assessments to confirm diagnosis 113 (Evidence: Strong).
  • MRI for Imaging Confirmation: Utilize MRI to identify characteristic spinal cord changes 16 (Evidence: Strong).
  • Supportive Physical Therapy: Initiate physical therapy to maintain muscle strength and mobility 1 (Evidence: Moderate).
  • Monitor for Early Signs of Progression: Regular follow-up to detect early signs of neurological deterioration 118 (Evidence: Moderate).
  • Consult Neurology for Complex Cases: Refer to neurology for advanced management in refractory or complex scenarios 118 (Evidence: Moderate).
  • Use Steroids with Caution: Consider short-term corticosteroid therapy in acute exacerbations, monitoring for side effects 118 (Evidence: Moderate).
  • Avoid High-Dose or Long-Term Use of Gabapentinoids: Exercise caution with gabapentinoids due to potential neurotoxicity 118 (Evidence: Moderate).
  • Multidisciplinary Rehabilitation: Implement comprehensive rehabilitation programs for functional recovery 1 (Evidence: Moderate).
  • Tailored Management in Special Populations: Adjust treatment strategies based on age, comorbidities, and specific risk factors 118 (Evidence: Expert opinion).

    • References

    1 Steel KAJ, Dunham JP, Leone C, Truini A, Treede RD, Phillips KG et al.. Preclinical assay of the effects of lacosamide, pregabalin, and tapentadol on the rat N1 spinal somatosensory evoked potential. Pain 2026. link 2 Kieves NR, Howard J, Lerche P, Lakritz J, Aarnes TK. Effectiveness of tapentadol hydrochloride for treatment of orthopedic pain in dogs: A pilot study. The Canadian veterinary journal = La revue veterinaire canadienne 2020. link 3 Ouyang H, Wang P, Huang W, Li Q, Nie B, Zeng W. Spinal antinociceptive action of amiloride and its interaction with tizanidine in the rat formalin test. Pain research & management 2015. link 4 Dickenson AH, Dray A. Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. British journal of pharmacology 1991. link 5 Davies J, Johnston SE. Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord. British journal of pharmacology 1984. link 6 Leone CM, di Pietro G, di Stefano G, Quesada C, Salameh C, Perchet C et al.. A multicentre randomized double-blind placebo-controlled study of lacosamide, pregabalin, and tapentadol on spinal pain biomarkers. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2026. link 7 Leino T, Lehtimäki J, Koivisto A, Haapalinna A, Pesonen U. Fadolmidine - Favourable adverse effects profile for spinal analgesia suggested by in vitro and in vivo models. European journal of pharmacology 2020. link 8 Jin M, Shi D, Jin H, Zhou Z, Wang C. The inhibitory effects of shikonin and β,β-dimethylacrylshikonin on tramadol metabolism in vitro and in vivo. The Journal of pharmacy and pharmacology 2020. link 9 Suzuki K, Naito T, Tanaka H, Yamada Y, Itoh K, Kawakami J. A Reversed-Phase Mode LC-MS/MS Method Using a Polysaccharide Chiral Selector for Simultaneous Quantitation of Each Enantiomer of Tramadol and its Metabolites in Human Plasma and Evaluation of CYP-Mediated Stereoselective Demethylation. Therapeutic drug monitoring 2020. link 10 Yang T, Du S, Liu X, Ye X, Wei X. Withdrawal from spinal application of remifentanil induces long-term potentiation of c-fiber-evoked field potentials by activation of Src family kinases in spinal microglia. Neurochemical research 2018. link 11 Kannampalli P, Poli SM, Boléa C, Sengupta JN. Analgesic effect of ADX71441, a positive allosteric modulator (PAM) of GABA. Neuropharmacology 2017. link 12 Gunia-Krzyżak A, Żesławska E, Bareyre FM, Nitek W, Waszkielewicz AM, Marona H. Physicochemical and biological evaluation of a cinnamamide derivative R,S-(2E)-1-(3-hydroxypiperidin-1-yl)-3-phenylprop-2-en-1-one (KM-608) for nervous system disorders. Chemical biology & drug design 2017. link 13 Higgs M, Hackworth RJ, John K, Riffenburgh R, Tomlin J, Wamsley B. The Intraoperative Effect of Methadone on Somatosensory Evoked Potentials. Journal of neurosurgical anesthesiology 2017. link 14 Wang QH, Han NR, Dai NY, Wu RJ, Wu JS. Analgesic effects and structural elucidation of two new flavone C-glycosides from Artemisa sacrorum. Chinese journal of natural medicines 2015. link30080-7) 15 Safrany-Fark A, Petrovszki Z, Kekesi G, Keresztes C, Benedek G, Horvath G. Telemetry monitoring for non-invasive assessment of changes in core temperature after spinal drug administration in freely moving rats. Journal of pharmacological and toxicological methods 2015. link 16 Mauger AR, Hopker JG. The effect of acetaminophen ingestion on cortico-spinal excitability. Canadian journal of physiology and pharmacology 2013. link 17 Göhler K, Brett M, Smit JW, Rengelshausen J, Terlinden R. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. International journal of clinical pharmacology and therapeutics 2013. link 18 Pepic D, Nikolic MS, Grujic S, Lausevic M, Djonlagic J. Release behaviour of carbamazepine-loaded poly(ε-caprolactone)/poly(ethylene oxide) microspheres. Journal of microencapsulation 2013. link 19 Ohsawa M, Mutoh J, Yamamoto S, Ono H, Hisa H. Effect of spinally administered simvastatin on the formalin-induced nociceptive response in mice. Journal of pharmacological sciences 2012. link 20 Sporkert F, Brunel C, Augsburger MP, Mangin P. Fatal tolperisone poisoning: autopsy and toxicology findings in three suicide cases. Forensic science international 2012. link 21 Belknap JK. The pharmacologic basis for the treatment of developmental and acute laminitis. The Veterinary clinics of North America. Equine practice 2010. link 22 Kaminski K, Kaminska E, Adrjanowicz K, Grzybowiska K, Wlodarczyk P, Paluch M et al.. Dielectric relaxation study on tramadol monohydrate and its hydrochloride salt. Journal of pharmaceutical sciences 2010. link 23 Honda K, Horikawa K, Ando S, Koga K, Kawata S, Migita K et al.. The spinal muscarinic M(1) receptors and GABA(A) receptors contribute to the McN-A-343-induced antinociceptive effects during thermal stimulation of mice. Journal of pharmacological sciences 2008. link 24 Kozer E, Levichek Z, Hoshino N, Kapur B, Leombruno J, Taguchi N et al.. The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. Anesthesia and analgesia 2008. link 25 Yue CQ, Ye J, Li CL, Li RT, Sun Q. Antinociceptive effects of the novel spirocyclopiperazinium salt compound LXM-10 in mice. Pharmacology, biochemistry, and behavior 2007. link 26 Okura T, Komiyama N, Morita Y, Kimura M, Yamada S. Different effects of morphine and morphine-6beta-glucuronide on formalin-evoked spinal glutamate release in conscious and freely moving rats. Neuroscience letters 2007. link 27 Mizoguchi H, Nakayama D, Watanabe H, Ito K, Sakurada W, Sawai T et al.. Involvement of spinal mu1-opioid receptors on the Tyr-d-Arg-Phe-sarcosine-induced antinociception. European journal of pharmacology 2006. link 28 Symonds KD, MacAllister CG, Erkert RS, Payton ME. Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome. American journal of veterinary research 2006. link 29 Tsvyetlynska NA, Hill RH, Grillner S. Role of AMPA receptor desensitization and the side effects of a DMSO vehicle on reticulospinal EPSPs and locomotor activity. Journal of neurophysiology 2005. link 30 Granados-Soto V, Argüelles CF. Synergic antinociceptive interaction between tramadol and gabapentin after local, spinal and systemic administration. Pharmacology 2005. link 31 Campanero MA, García-Quetglas E, Sádaba B, Azanza JR. Simultaneous stereoselective analysis of tramadol and its primary phase I metabolites in plasma by liquid chromatography. Application to a pharmacokinetic study in humans. Journal of chromatography. A 2004. link 32 Rouini MR, Asadipour A, Ardakani YH, Aghdasi F. Liquid chromatography method for determination of mefenamic acid in human serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004. link 33 Roerig SC. Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. Annals of the New York Academy of Sciences 2003. link 34 Liu HC, Jin SM, Wang YL. Gender-related differences in pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in rats. Acta pharmacologica Sinica 2003. link 35 Todorovic SM, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain research 2002. link03350-4) 36 Heughan CE, Allen GV, Chase TD, Sawynok J. Peripheral amitriptyline suppresses formalin-induced Fos expression in the rat spinal cord. Anesthesia and analgesia 2002. link 37 Chen SR, Pan HL. Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats. Anesthesiology 2001. link 38 Raffa RB, Stone DJ, Tallarida RJ. Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. European journal of pharmacology 2001. link00722-1) 39 Advokat C, Duke M, Zeringue R. Dissociation of (-) baclofen-induced effects on the tail withdrawal and hindlimb flexor reflexes of chronic spinal rats. Pharmacology, biochemistry, and behavior 1999. link00026-x) 40 Klamt JG, Posner J. Effects of lamotrigine on pain-induced chemo-somatosensory evoked potentials. Anaesthesia 1999. link 41 Nishiyama T, Gyermek L, Lee C, Kawasaki-Yatsugi S, Yamaguchi T. The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats. Anesthesia and analgesia 1999. link 42 Koyama N, Hanai F, Yokota T. Does intravenous administration of GABA(A) receptor antagonists induce both descending antinociception and touch-evoked allodynia?. Pain 1998. link00061-X) 43 Hara Y, Nakaya H, Ally A, Kondo H. Effects of central nervous stimulants on spino-bulbo-spinal reflex potentials in cats. The Journal of veterinary medical science 1997. link 44 Diaz A, Mayet S, Dickenson AH. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. European journal of pharmacology 1997. link01118-7) 45 Blackburn-Munro G, Fleetwood-Walker SM. The effects of Na+ channel blockers on somatosensory processing by rat dorsal horn neurones. Neuroreport 1997. link 46 Lehr GJ. Determination of diphenoxylate hydrochloride and atropine sulfate in combination drug formulations by liquid chromatography. Journal of AOAC International 1996. link 47 Rady JJ, Fujimoto JM. Supraspinal delta 2 opioid agonist analgesia in Swiss-Webster mice involves spinal GABAA receptors. Pharmacology, biochemistry, and behavior 1996. link02150-7) 48 Omote K, Kawamata M, Satoh O, Iwasaki H, Namiki A. Spinal antinociceptive action of an N-Type voltage-dependent calcium channel blocker and the synergistic interaction with morphine. Anesthesiology 1996. link 49 Dei S, Bellucci C, Ghelardini C, Romanelli MN, Spampinato S. Synthesis, characterization and pharmacological profile of tropicamide enantiomers. Life sciences 1996. link00208-1) 50 Bernards CM. Effect of (hydroxypropyl)-beta-cyclodextrin on flux of morphine, fentanyl, sufentanil, and alfentanil through the spinal meninges of monkey. Journal of pharmaceutical sciences 1994. link 51 Hammond DL, Washington JD. Antagonism of L-baclofen-induced antinociception by CGP 35348 in the spinal cord of the rat. European journal of pharmacology 1993. link90961-g) 52 Horan PJ, Wild KD, Kazmierski WM, Ferguson R, Hruby VJ, Weber SJ et al.. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action. European journal of pharmacology 1993. link90348-l) 53 Ishizuki M, Yanagisawa M. Antinociceptive effects of tizanidine, diazepam and eperisone in isolated spinal cord-tail preparations of newborn rat. Pain 1992. link90136-Y) 54 Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A et al.. General pharmacological properties of the new vasodilator flosequinan. Arzneimittel-Forschung 1992. link 55 Vaught JL, Raffa RB. Centrally-mediated antinociceptive action of RWJ-22757 (formerly McN-5195): involvement of spinal descending inhibitory pathways (an hypothesis). Life sciences 1991. link90338-c) 56 Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Iwamoto K. Enhanced entry of ciprofloxacin into the rat central nervous system induced by fenbufen. The Journal of pharmacology and experimental therapeutics 1991. link 57 Pertovaara A, Kauppila T, Jyväsjärvi E, Kalso E. Involvement of supraspinal and spinal segmental alpha-2-adrenergic mechanisms in the medetomidine-induced antinociception. Neuroscience 1991. link90089-7) 58 Dickenson A, Hughes C, Rueff A, Dray A. A spinal mechanism of action is involved in the antinociception produced by the capsaicin analogue NE 19550 (olvanil). Pain 1990. link90032-9) 59 Bell JA, Shannon HE. Partial agonists of the morphine type: facilitative effects on electrophysiologically recorded C-fiber reflexes in the cat. Neuropharmacology 1988. link90188-8) 60 Russell RD, Leslie JB, Su YF, Watkins WD, Chang KJ. Interaction between highly selective mu and delta opioids in vivo at the rat spinal cord. NIDA research monograph 1986. link 61 Zorn SH, Enna SJ. GABA uptake inhibitors produce a greater antinociceptive response in the mouse tail-immersion assay than other types of GABAergic drugs. Life sciences 1985. link90008-6) 62 Kubota A, Satoh M, Takagi H. Suppressive effect of ciramadol on the bradykinin-induced activities of the lamina V-type cells of the rat spinal dorsal horn. Journal of pharmacobio-dynamics 1984. link 63 Yokota T, Nishikawa N. Effects of picrotoxin upon response characteristics of wide dynamic range neurons in the spinal cord of cat and monkey. Neuroscience letters 1982. link90067-2)

    Original source

    1. [1]
      Preclinical assay of the effects of lacosamide, pregabalin, and tapentadol on the rat N1 spinal somatosensory evoked potential. — Steel KAJ, Dunham JP, Leone C, Truini A, Treede RD, Phillips KG et al. Pain (2026)
    2. [2]
      Effectiveness of tapentadol hydrochloride for treatment of orthopedic pain in dogs: A pilot study. — Kieves NR, Howard J, Lerche P, Lakritz J, Aarnes TK The Canadian veterinary journal = La revue veterinaire canadienne (2020)
    3. [3]
      Spinal antinociceptive action of amiloride and its interaction with tizanidine in the rat formalin test. — Ouyang H, Wang P, Huang W, Li Q, Nie B, Zeng W Pain research & management (2015)
    4. [4]
      Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. — Dickenson AH, Dray A British journal of pharmacology (1991)
    5. [5]
      Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord. — Davies J, Johnston SE British journal of pharmacology (1984)
    6. [6]
      A multicentre randomized double-blind placebo-controlled study of lacosamide, pregabalin, and tapentadol on spinal pain biomarkers. — Leone CM, di Pietro G, di Stefano G, Quesada C, Salameh C, Perchet C et al. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026)
    7. [7]
      Fadolmidine - Favourable adverse effects profile for spinal analgesia suggested by in vitro and in vivo models. — Leino T, Lehtimäki J, Koivisto A, Haapalinna A, Pesonen U European journal of pharmacology (2020)
    8. [8]
      The inhibitory effects of shikonin and β,β-dimethylacrylshikonin on tramadol metabolism in vitro and in vivo. — Jin M, Shi D, Jin H, Zhou Z, Wang C The Journal of pharmacy and pharmacology (2020)
    9. [9]
      A Reversed-Phase Mode LC-MS/MS Method Using a Polysaccharide Chiral Selector for Simultaneous Quantitation of Each Enantiomer of Tramadol and its Metabolites in Human Plasma and Evaluation of CYP-Mediated Stereoselective Demethylation. — Suzuki K, Naito T, Tanaka H, Yamada Y, Itoh K, Kawakami J Therapeutic drug monitoring (2020)
    10. [10]
      Withdrawal from spinal application of remifentanil induces long-term potentiation of c-fiber-evoked field potentials by activation of Src family kinases in spinal microglia. — Yang T, Du S, Liu X, Ye X, Wei X Neurochemical research (2018)
    11. [11]
      Analgesic effect of ADX71441, a positive allosteric modulator (PAM) of GABA — Kannampalli P, Poli SM, Boléa C, Sengupta JN Neuropharmacology (2017)
    12. [12]
      Physicochemical and biological evaluation of a cinnamamide derivative R,S-(2E)-1-(3-hydroxypiperidin-1-yl)-3-phenylprop-2-en-1-one (KM-608) for nervous system disorders. — Gunia-Krzyżak A, Żesławska E, Bareyre FM, Nitek W, Waszkielewicz AM, Marona H Chemical biology & drug design (2017)
    13. [13]
      The Intraoperative Effect of Methadone on Somatosensory Evoked Potentials. — Higgs M, Hackworth RJ, John K, Riffenburgh R, Tomlin J, Wamsley B Journal of neurosurgical anesthesiology (2017)
    14. [14]
      Analgesic effects and structural elucidation of two new flavone C-glycosides from Artemisa sacrorum. — Wang QH, Han NR, Dai NY, Wu RJ, Wu JS Chinese journal of natural medicines (2015)
    15. [15]
      Telemetry monitoring for non-invasive assessment of changes in core temperature after spinal drug administration in freely moving rats. — Safrany-Fark A, Petrovszki Z, Kekesi G, Keresztes C, Benedek G, Horvath G Journal of pharmacological and toxicological methods (2015)
    16. [16]
      The effect of acetaminophen ingestion on cortico-spinal excitability. — Mauger AR, Hopker JG Canadian journal of physiology and pharmacology (2013)
    17. [17]
      Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. — Göhler K, Brett M, Smit JW, Rengelshausen J, Terlinden R International journal of clinical pharmacology and therapeutics (2013)
    18. [18]
      Release behaviour of carbamazepine-loaded poly(ε-caprolactone)/poly(ethylene oxide) microspheres. — Pepic D, Nikolic MS, Grujic S, Lausevic M, Djonlagic J Journal of microencapsulation (2013)
    19. [19]
      Effect of spinally administered simvastatin on the formalin-induced nociceptive response in mice. — Ohsawa M, Mutoh J, Yamamoto S, Ono H, Hisa H Journal of pharmacological sciences (2012)
    20. [20]
      Fatal tolperisone poisoning: autopsy and toxicology findings in three suicide cases. — Sporkert F, Brunel C, Augsburger MP, Mangin P Forensic science international (2012)
    21. [21]
      The pharmacologic basis for the treatment of developmental and acute laminitis. — Belknap JK The Veterinary clinics of North America. Equine practice (2010)
    22. [22]
      Dielectric relaxation study on tramadol monohydrate and its hydrochloride salt. — Kaminski K, Kaminska E, Adrjanowicz K, Grzybowiska K, Wlodarczyk P, Paluch M et al. Journal of pharmaceutical sciences (2010)
    23. [23]
      The spinal muscarinic M(1) receptors and GABA(A) receptors contribute to the McN-A-343-induced antinociceptive effects during thermal stimulation of mice. — Honda K, Horikawa K, Ando S, Koga K, Kawata S, Migita K et al. Journal of pharmacological sciences (2008)
    24. [24]
      The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. — Kozer E, Levichek Z, Hoshino N, Kapur B, Leombruno J, Taguchi N et al. Anesthesia and analgesia (2008)
    25. [25]
      Antinociceptive effects of the novel spirocyclopiperazinium salt compound LXM-10 in mice. — Yue CQ, Ye J, Li CL, Li RT, Sun Q Pharmacology, biochemistry, and behavior (2007)
    26. [26]
      Different effects of morphine and morphine-6beta-glucuronide on formalin-evoked spinal glutamate release in conscious and freely moving rats. — Okura T, Komiyama N, Morita Y, Kimura M, Yamada S Neuroscience letters (2007)
    27. [27]
      Involvement of spinal mu1-opioid receptors on the Tyr-d-Arg-Phe-sarcosine-induced antinociception. — Mizoguchi H, Nakayama D, Watanabe H, Ito K, Sakurada W, Sawai T et al. European journal of pharmacology (2006)
    28. [28]
      Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome. — Symonds KD, MacAllister CG, Erkert RS, Payton ME American journal of veterinary research (2006)
    29. [29]
      Role of AMPA receptor desensitization and the side effects of a DMSO vehicle on reticulospinal EPSPs and locomotor activity. — Tsvyetlynska NA, Hill RH, Grillner S Journal of neurophysiology (2005)
    30. [30]
      Synergic antinociceptive interaction between tramadol and gabapentin after local, spinal and systemic administration. — Granados-Soto V, Argüelles CF Pharmacology (2005)
    31. [31]
      Simultaneous stereoselective analysis of tramadol and its primary phase I metabolites in plasma by liquid chromatography. Application to a pharmacokinetic study in humans. — Campanero MA, García-Quetglas E, Sádaba B, Azanza JR Journal of chromatography. A (2004)
    32. [32]
      Liquid chromatography method for determination of mefenamic acid in human serum. — Rouini MR, Asadipour A, Ardakani YH, Aghdasi F Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2004)
    33. [33]
      Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. — Roerig SC Annals of the New York Academy of Sciences (2003)
    34. [34]
      Gender-related differences in pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in rats. — Liu HC, Jin SM, Wang YL Acta pharmacologica Sinica (2003)
    35. [35]
      Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. — Todorovic SM, Meyenburg A, Jevtovic-Todorovic V Brain research (2002)
    36. [36]
      Peripheral amitriptyline suppresses formalin-induced Fos expression in the rat spinal cord. — Heughan CE, Allen GV, Chase TD, Sawynok J Anesthesia and analgesia (2002)
    37. [37]
      Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats. — Chen SR, Pan HL Anesthesiology (2001)
    38. [38]
      Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. — Raffa RB, Stone DJ, Tallarida RJ European journal of pharmacology (2001)
    39. [39]
      Dissociation of (-) baclofen-induced effects on the tail withdrawal and hindlimb flexor reflexes of chronic spinal rats. — Advokat C, Duke M, Zeringue R Pharmacology, biochemistry, and behavior (1999)
    40. [40]
      Effects of lamotrigine on pain-induced chemo-somatosensory evoked potentials. — Klamt JG, Posner J Anaesthesia (1999)
    41. [41]
      The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats. — Nishiyama T, Gyermek L, Lee C, Kawasaki-Yatsugi S, Yamaguchi T Anesthesia and analgesia (1999)
    42. [42]
      Does intravenous administration of GABA(A) receptor antagonists induce both descending antinociception and touch-evoked allodynia? — Koyama N, Hanai F, Yokota T Pain (1998)
    43. [43]
      Effects of central nervous stimulants on spino-bulbo-spinal reflex potentials in cats. — Hara Y, Nakaya H, Ally A, Kondo H The Journal of veterinary medical science (1997)
    44. [44]
      BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. — Diaz A, Mayet S, Dickenson AH European journal of pharmacology (1997)
    45. [45]
      The effects of Na+ channel blockers on somatosensory processing by rat dorsal horn neurones. — Blackburn-Munro G, Fleetwood-Walker SM Neuroreport (1997)
    46. [46]
      Determination of diphenoxylate hydrochloride and atropine sulfate in combination drug formulations by liquid chromatography. — Lehr GJ Journal of AOAC International (1996)
    47. [47]
      Supraspinal delta 2 opioid agonist analgesia in Swiss-Webster mice involves spinal GABAA receptors. — Rady JJ, Fujimoto JM Pharmacology, biochemistry, and behavior (1996)
    48. [48]
      Spinal antinociceptive action of an N-Type voltage-dependent calcium channel blocker and the synergistic interaction with morphine. — Omote K, Kawamata M, Satoh O, Iwasaki H, Namiki A Anesthesiology (1996)
    49. [49]
      Synthesis, characterization and pharmacological profile of tropicamide enantiomers. — Dei S, Bellucci C, Ghelardini C, Romanelli MN, Spampinato S Life sciences (1996)
    50. [50]
      Effect of (hydroxypropyl)-beta-cyclodextrin on flux of morphine, fentanyl, sufentanil, and alfentanil through the spinal meninges of monkey. — Bernards CM Journal of pharmaceutical sciences (1994)
    51. [51]
      Antagonism of L-baclofen-induced antinociception by CGP 35348 in the spinal cord of the rat. — Hammond DL, Washington JD European journal of pharmacology (1993)
    52. [52]
      Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action. — Horan PJ, Wild KD, Kazmierski WM, Ferguson R, Hruby VJ, Weber SJ et al. European journal of pharmacology (1993)
    53. [53]
      Antinociceptive effects of tizanidine, diazepam and eperisone in isolated spinal cord-tail preparations of newborn rat. — Ishizuki M, Yanagisawa M Pain (1992)
    54. [54]
      General pharmacological properties of the new vasodilator flosequinan. — Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A et al. Arzneimittel-Forschung (1992)
    55. [55]
      Centrally-mediated antinociceptive action of RWJ-22757 (formerly McN-5195): involvement of spinal descending inhibitory pathways (an hypothesis). — Vaught JL, Raffa RB Life sciences (1991)
    56. [56]
      Enhanced entry of ciprofloxacin into the rat central nervous system induced by fenbufen. — Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Iwamoto K The Journal of pharmacology and experimental therapeutics (1991)
    57. [57]
      Involvement of supraspinal and spinal segmental alpha-2-adrenergic mechanisms in the medetomidine-induced antinociception. — Pertovaara A, Kauppila T, Jyväsjärvi E, Kalso E Neuroscience (1991)
    58. [58]
      A spinal mechanism of action is involved in the antinociception produced by the capsaicin analogue NE 19550 (olvanil). — Dickenson A, Hughes C, Rueff A, Dray A Pain (1990)
    59. [59]
      Partial agonists of the morphine type: facilitative effects on electrophysiologically recorded C-fiber reflexes in the cat. — Bell JA, Shannon HE Neuropharmacology (1988)
    60. [60]
      Interaction between highly selective mu and delta opioids in vivo at the rat spinal cord. — Russell RD, Leslie JB, Su YF, Watkins WD, Chang KJ NIDA research monograph (1986)
    61. [61]
      GABA uptake inhibitors produce a greater antinociceptive response in the mouse tail-immersion assay than other types of GABAergic drugs. — Zorn SH, Enna SJ Life sciences (1985)
    62. [62]
      Suppressive effect of ciramadol on the bradykinin-induced activities of the lamina V-type cells of the rat spinal dorsal horn. — Kubota A, Satoh M, Takagi H Journal of pharmacobio-dynamics (1984)
    63. [63]
      Effects of picrotoxin upon response characteristics of wide dynamic range neurons in the spinal cord of cat and monkey. — Yokota T, Nishikawa N Neuroscience letters (1982)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG